PPL-100, a promising protease inhibitor
Indication
HIV/AIDS
Development status
Phase I repeat dosing study completed
Patents
U.S. granted and World pending
HIV/AIDS - Protease Inhibitor Program
Ambrilia has developed a family of lysine based compounds that are potent inhibitors or HIV protease. One of these compounds, PPL-100, has the potential of being a best-in-class HIV protease inhibitor. PPL-100 has been shown to possess advantageous properties such as a high genetic barrier, a low cross-resistance profile and no requirement for ritonavir boosting.
To date, all approved protease inhibitors are co- administered with ritonavir (or other similar compound) which is required to boost bio-availability of the drug. Such a drug combination increases the possibility of adverse events, a protease inhibitor that does not require boosting is advantageous. Furthermore, many currently approved HIV protease inhibitors possess a low genetic barrier, such that viral resistance can be more easily achieved, as well as cross-resistance to antiviral drugs.
Licensing & Divestment
Ambrilia's protease inhibitors are available for licensing or divestment.
For more information please contact:
Richard La Rue, LL.L, D.D.N.
Interim President & CEO
Tel.: (514) 751-2003 ex. 233
e-mail: rlarue@ambrilia.com